Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 703 participants.
Also called NCT02906930
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 703 participants
- Sponsor
- Registry
-
NCT02906930 -
2015-005622-19
-
- Other papers using this trial's data
- Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Algeria, Bulgaria, Czechia, Italy, Japan, Mexico, Romania, Russia, Serbia, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT02906930. Randomized; double masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2017-10-30 (actual). Results posted on 2020-02-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
- Acronym
- PIONEER 1
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02906930- Content hash
feab280d5bad5f4232347cbba91d3b7dcdadb51cb4449a40f4775e83f0d222fc